FDA's New Oncology Guidance Signals The Next Phase Of Drug Development Reform

By Zaher Nahle, Ph.D., MPA

Earlier this year, the U.S. FDA released a landmark draft guidance encouraging the use of new approach methodologies (NAMs) — including advanced cell systems, computational tools, and organ-on-chip technologies — in drug development. For many observers, that document represented an important policy statement. For those of us who have worked to modernize biomedical research, it signaled something more profound: the beginning of a transition away from animal testing as the default framework for evaluating medical products.

Now the FDA has taken another significant step — a newly released draft guidance focused on oncology pharmaceuticals. The draft may appear technical and narrowly focused, but it represents one of the clearest examples yet of how regulatory reform is beginning to translate into practice. The guidance encourages streamlined nonclinical safety assessments for certain cancer therapies and explicitly seeks to reduce unnecessary animal testing while maintaining patient safety.

The importance of this development extends beyond oncology. In a recent review examining path dependency in biomedical research, I described how animal testing became embedded in drug development through a process of institutional lock-in. Over decades, scientific practices, regulatory expectations, international harmonization efforts, and organizational incentives converged to create a system in which animal studies became the default pathway for advancing new therapies. Once established, that framework proved remarkably resistant to change.

The FDA Modernization Act 2.0, enacted in 2022, created a critical juncture by removing statutory language that had long been interpreted as requiring animal testing before human clinical trials. But legislative reform alone, the main hurdle, was never sufficient. The larger challenge has always been implementation.

Notably, this very challenge was the impetus behind the drafting of the FDA Modernization Act 3.0, which is making its way through the legislative process. The act will ensure the implementation of the FDA Modernization Act 2.0 and that FDA regulations will no longer mandate animal testing of new drugs where federal law does not require it. Of note, on Dec. 16, 2025, the U.S. Senate unanimously passed S. 355 (FDA Modernization Act 3.0). On May 21, 2026, the U.S. House Energy and Commerce Committee passed H.R. 2821, a companion bill, bringing the legislation one major step closer to enactment.

The overarching question is whether regulators would simply permit alternatives to animal testing or actively incorporate them into regulatory decision-making.

The answer began to emerge in April 2025 when the FDA announced plans to phase out animal testing requirements for monoclonal antibodies and expand the use of human-relevant approaches for safety assessment. As described earlier, the agency followed up in March 2026 with a broader draft guidance establishing a regulatory framework for the use of NAMs across drug development. The newly released oncology guidance now represents another important step in translating those principles into therapeutic area-specific regulatory practice.

Notably, many of the products addressed in the new guidance — including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates — are among the fastest growing and most commercially important segments of modern therapeutics. This suggests that the FDA's reforms are beginning to reach the center rather than the margins of pharmaceutical innovation.

The document explicitly acknowledges circumstances in which animal studies may be reduced, streamlined, or replaced by weight-of-evidence assessments drawing upon existing scientific knowledge, pharmacology, clinical information, and fit-for-purpose new approach methodologies.

For several important categories of oncology biologics, including PD-(L)1 blocking antibodies and CD3 bispecific T cell engagers, the FDA indicates that assessments of chronic effects may be based on weight-of-evidence approaches in lieu of traditional three-month animal toxicology studies.

Perhaps even more important, the guidance recognizes a fundamental scientific reality: when no pharmacologically relevant animal species exists, meaningful safety assessment may depend more on mechanistic understanding and human-relevant evidence than on conducting animal studies for their own sake.

This development closely mirrors the trajectory I outlined in my 2026 review, which I mentioned earlier, examining path dependency in biomedical research. In that analysis, I argued that meaningful reform would not occur merely through legislative change but through a gradual reorientation of regulatory decision-making away from animal testing as a default requirement and toward evidence evaluated on its scientific relevance, mechanistic understanding, and predictive value for human outcomes. I further suggested that the FDA Modernization Act 2.0 represented a critical juncture capable of initiating this transition, provided regulators translated new statutory flexibility into regulatory practice.

The FDA's willingness to accept weight-of-evidence assessments and mechanistically informed approaches in lieu of certain animal studies represents an early example of that predicted evolution. What was once a theoretical pathway for reform is increasingly becoming operational regulatory policy.

This represents a notable shift in regulatory thinking. Historically, animal studies often functioned as a procedural requirement. The question was not whether they generated the most informative evidence but whether they had been completed. Increasingly, the FDA appears to be moving toward a different standard: whether the evidence is fit for purpose and predictive of human outcomes.

That distinction matters. For decades, biomedical innovation has operated within a framework that often prioritized conformity to established testing paradigms over scientific relevance. Yet modern technologies now allow researchers to investigate human biology directly through sophisticated cellular systems, organoids, organ-on-chip platforms, computational modeling, and integrated data-driven approaches. These tools create an opportunity to generate evidence that is not merely different from animal testing but potentially more informative for human health.

Importantly, this guidance should not be viewed as the endpoint of reform.

As my path dependency analysis emphasized, entrenched systems frequently absorb change by treating new approaches as complements rather than replacements. The risk is not necessarily resistance but rather accommodation. New methods can be incorporated into existing systems while leaving the underlying paradigm largely intact.

Whether this guidance becomes a transformative milestone or simply an incremental adjustment will depend on what follows. Continued progress will require clear implementation pathways, measurable reductions in unnecessary animal testing, broader regulatory acceptance of human-relevant evidence, and sustained investment in modern scientific platforms. The success of reform should ultimately be measured not by the number of guidance documents issued but by whether regulatory decision-making increasingly rewards evidence that is most relevant to human biology.

Nevertheless, the direction of travel is becoming increasingly difficult to ignore. The progression from FDA Modernization Act 2.0, to the FDA's 2025 monoclonal antibody initiative, to the 2026 NAMs framework, and now to this oncology guidance follows a trajectory that many reform advocates anticipated but that our path dependency analysis explicitly described: the gradual replacement of inherited testing requirements with a more flexible, human-relevant, evidence-based regulatory paradigm.

In the language of path dependency, another critical juncture may be emerging. The question is no longer whether alternatives to animal testing exist. The question is whether the biomedical enterprise is prepared to make them the new default as they become ready for prime time. FDA's new guidance on oncology pharmaceuticals helps move the field in that direction.

About The Author

Zaher Nahle, Ph.D., MPA, is a science policy expert, biomedical scientist, and senior advisor whose work has helped shape reforms at the U.S. Food and Drug Administration and National Institutes of Health. He serves as senior scientific advisor to the Center for a Humane Economy and Animal Wellness Action and is the founder of The Ivyctory Group, a market research and life sciences advisory firm. Nahle has held executive leadership positions at medical foundations, including CEO, chief scientific officer, and vice president for research. Earlier in his career, he led independent research programs, was a founding investigator of an NIH-funded data management and coordinating center, published in leading journals, including Nature, and received competitive grants and awards from organizations including the American Heart Association and the U.S. Department of Defense. He earned a Ph.D. in physiology and biophysics from the Stony Brook University/Cold Spring Harbor Laboratory joint program and an MPA from Harvard University.